How to Buy Protagonist Therapeutics Stock

Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.

Protagonist Therapeutics stock last closed at $112.86, up 1.27% from the previous day, and has increased 109.31% in one year. It has overperformed other stocks in the Biotechnology industry by 1.81 percentage points. Protagonist Therapeutics stock is currently +128.55% from its 52-week low of $49.38, and -1.42% from its 52-week high of $114.49.

At the moment, there are 64.31M PTGX shares outstanding. The market capitalization of PTGX is $7.26B. In the past 24 hours, 1.53M PTGX shares were traded.

How to Buy Protagonist Therapeutics Stock

Wondering how to invest in Protagonist Therapeutics stock? Here's how.

  1. Figure out where to buy Protagonist Therapeutics stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you choose where to buy Protagonist Therapeutics stock.
  2. Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
  3. Put funds into your investment account: Pick your method of payment and add your information.
  4. Analyze Protagonist Therapeutics stock: The Protagonist Therapeutics ticker symbol is PTGX. Is Protagonist Therapeutics stock a good investment? Should you buy shares of PTGX? How do PTGX's underlying business fundamentals look? Do top analysts think Protagonist Therapeutics is a good buy? Why has PTGX's stock price moved recently? (Hint: Our stock market analysis website can help you decide if PTGX is a good stock to buy).
  5. Make your PTGX buy order: Decide if you will purchase PTGX shares at the current market price or use a limit order to purchase PTGX shares at a specific price.
  6. Keep an eye on your PTGX investment: Create a watchlist to watch your new investment in Protagonist Therapeutics shares.

Step 1: Figure out where to buy Protagonist Therapeutics stock

You will need a brokerage account to access the NASDAQ market and buy PTGX stock.

A brokerage account enables you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.

Our favorite brokerage: eToro

We believe that eToro is the best place to buy stocks. Here's why:

  • Invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to global markets: From Tech to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
  • Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
  • Security: eToro is a regulated and licensed brokerage platform.
  • Buy other financial assets: Such as ETFs and cryptos.

Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.

Open eToro Account
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.

Step 2: Open your brokerage account

Now that you've picked the best brokerage, the next step is to fill out some personal information so you are able to invest in PTGX today.

How to Open a New Investment Account on eToro

  1. Click here to get started.
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
  2. Provide your personal details to create a new brokerage account.
  1. Submit your info by hitting the "Create Account" button.
  2. Get started with eToro today
    eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 3: Put funds into your investment account

Now that you have created your account on our top ranked stock app, you need to deposit funds:

Watch this video walkthrough if you need help depositing funds into your new investment account.

Get started with eToro today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Step 4: Analyze Protagonist Therapeutics stock

After you have decided on the best place to buy Protagonist Therapeutics stock, it's very important to analyze their stock prior to investing, so you truly comprehend the risk as well as the upside.

Protagonist Therapeutics Metrics

PTGX Price
$112.86
1w %
2.8%
1y %
109.31%
5y %
165.74%
P/E
-62.35x
P/B
11.07x
P/S
99.17x
PEG
N/A
Revenue
$74.06M
Earnings
-$114.71M
Fore. Rev. Growth
25.48%
Fore. Earn. Growth
N/A
Market Cap
$7.26B
Next Earnings
N/A
Next Dividend
N/A

Protagonist Therapeutics Due Diligence Checks

WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis in less time.

You can view all of the due diligence checks on PTGX's stock page.

Is PTGX stock properly valued?

Investors use many financial metrics, analyses, models, and charts to gauge PTGX's fair value.

Using relative valuations metrics:

  • PTGX could be overvalued based on its P/B ratio of 11.07x, relative to Biotechnology industry P/B ratio of 4.95x

You can do more valuation analysis on PTGX's stock here.

A quick look at PTGX Financials

Signs that PTGX is financially healthy:

  • PTGX has $547.79M in cash and short term investments. This is enough to cover its annual cash burn of $117.90M.
  • There are more short-term assets than short-term liabilities on the PTGX balance sheet.
  • PTGX has a low debt to equity ratio of 0.06.
  • Total PTGX debt is lower than 5 years ago, relative to shareholder equity.
  • PTGX has cash burn of 117895000. It has enough cash and short-term investments to cover this for at least one year.
  • There are more short-term assets than long-term liabilities on the PTGX balance sheet.

Signs that PTGX is not financially healthy:

  • PTGX profit margin has gone down from 27% to -154.9% in the past year.

Is Protagonist Therapeutics stock a Buy, Hold, or Sell, according to analysts?

Out of 12 Wall Street analysts who give recommendations on PTGX, the consensus analyst rating on PTGX is a Strong Buy

Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.

Most Recent PTGX Analyst Forecasts

Brian Cheng, a top 21% analyst from JP Morgan maintains PTGX with a strong buy rating and raises their PTGX price target from $95.00 to $106.00, on Mar 19, 2026.

Geoff Meacham, a top 12% analyst from Citigroup maintains PTGX with a strong buy rating and raises their PTGX price target from $115.00 to $125.00, on Mar 19, 2026.

Etzer Darout, a top 2% analyst from Barclays maintains PTGX with a strong buy rating and raises their PTGX price target from $113.00 to $119.00, on Mar 19, 2026.

Barclays's Etzer Darout raised their price target on Protagonist Therapeutics (NASDAQ: PTGX) by 5.3% from $113 to $119 on 2026/03/19. The analyst maintained their Strong Buy rating on the stock.

Protagonist Therapeutics announced FDA approval for ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of moderate-to-severe plaque psoriasis, and that ICOTYDE will be commercialized by Johnson & Johnson.

Raising their price target, Darout noted that the approval was obtained a few months ahead of investor expectations.

Richard Law, a top 33% analyst from Goldman Sachs maintains PTGX with a hold rating and raises their PTGX price target from $65.00 to $95.00, on Mar 3, 2026.

Tara Bancroft, a top 34% analyst from TD Cowen maintains PTGX with a strong buy rating and raises their PTGX price target from $90.00 to $100.00, on Feb 26, 2026.

You can dig deeper into what analysts are projecting on the Protagonist Therapeutics stock forecast page.

PTGX Technical Indicators

SMA10
107.4
SMA20
103.19
SMA50
102.3
SMA100
97.05
SMA200
87.5
MACD
3.05
MACD Signal
1.66
MACD Histogram
1.38
RSI
63.63
Stochastic %K
89.15
Stochastic %D
90.49
StochRSI %K
92.02
StochRSI %D
93.61

PTGX Earnings

Last year, PTGX revenue was $74.06M. In the past five year, PTGX's revenue has grown by 18.9% per year. This was slower than the Biotechnology industry average of 32.37%.

You can analyze PTGX's earnings and revenue performance here.

What are PTGX insiders up to?

In the past 12 months, insiders at PTGX have sold more shares than they have bought.

William D. Waddill, Director of PTGX, was the latest PTGX insider to buy. They bought $35,400.00 worth of PTGX shares on Jun 10, 2026.

Research more about who owns PTGX stock here.

Can I get consistent income from PTGX stock?

No, Protagonist Therapeutics doesn't provide an income stream by paying out dividends.

PTGX Social Trading Data

One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.

Click below to find out what other community members have to say.

Step 5: Make your PTGX buy order

There are two primary order types:

  • Market order: A market order is an order to buy or sell a stock at the best available price.
    Market orders are usually sufficient.
  • Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
    If you want to ensure you're buying or selling at an exact dollar amount, use a limit order.

Press the Open Trade button and your broker will execute the order.

If you need more help with investing in stocks on eToro, click the helpful video below:

Open eToro Account

Step 6: Keep an eye on your PTGX investment

Now that you own some shares in PTGX, you'll want to stay up-to-date on your shares.

Start a watchlist to get notified of important updates regarding your PTGX stock.

PTGX Feed

How to Buy Stock in Protagonist Therapeutics

To reiterate, here are the 6 steps for buying Protagonist Therapeutics stock:

  1. Figure out where to buy Protagonist Therapeutics stock
  2. Open your brokerage account
  3. Put funds into your investment account
  4. Analyze Protagonist Therapeutics stock
  5. Make your PTGX buy order
  6. Keep an eye on your PTGX investment

If you need a brokerage, eToro is our recommended option.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

If you would like to keep an eye on your new investment in Protagonist Therapeutics, get started below.

NASDAQ: PTGX
$112.86+1.42 (+1.27%)
Updated Jun 18, 2026
Open eToro Account
Your capital is at risk.
NASDAQ: PTGX
$112.86+1.42 (+1.27%)
Updated Jun 18, 2026
Open eToro Account
Your capital is at risk.

FAQ

How much does it cost to buy one Protagonist Therapeutics share?

As of Jun 18, 2026, it costs $112.86 to buy one share of Protagonist Therapeutics stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.089 shares of PTGX.

Get Started with eToro Today
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.

Is now a good time to buy Protagonist Therapeutics stock?

According to 12 Wall Street analysts who monitor Protagonist Therapeutics, their consensus recommendation is to buy Protagonist Therapeutics stock.

What is the best way to buy Protagonist Therapeutics stock?

One way to place an order for Protagonist Therapeutics stock is with a brokerage account.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.